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1. Introduction 
Professional antigen presenting cells, in particular dendritic cells (DCs) are central players in 
the immune response (Steinman & Banchereau 2007). Their function is dual; on the one hand 
DCs evoke strong immune responses against antigens that are considered hazardous, on the 
other hand DCs induce tolerance against self-antigens. To that end, DCs need to present 
antigen-derived peptides in the context of MHC class I or class II molecules to CD8+ and CD4+ 
T cells, respectively. It is the context in which these peptides are presented that determines the 
outcome of the immune response, immune activation versus tolerance. Consequently, DCs 
have become targets for immunotherapy against not only cancer and infectious disease, but 
also autoimmune diseases and transplantation rejection (Palucka et al.).   
Key to successful DC-based immunotherapy is the delivery of the antigen of interest, be it 
cancer, viral or auto-antigens, to DCs, as well as the delivery of molecules that dictate the 
immune stimulatory capacity of the DCs. Therefore, it is not surprising that much effort has 
been put in the development of vectors for genetic modification of DCs (Breckpot et al. 
2004c). Of these lentiviral vectors (LVs), often derived from human immunodeficiency virus 
type 1 (HIV-1) are amongst the most efficient gene delivery vehicles, for both in vitro and in 
vivo modification of DCs (Escors & Breckpot ; Breckpot et al. 2007a). In addition, these LVs 
were demonstrated to activate the innate immune system through interaction with amongst 
others Toll-like receptors (TLRs), a characteristic that makes LVs even better suited for 
immunotherapeutic approaches against cancer and infectious diseases (Breckpot et al. ; 
Brown et al. 2006a). As immune activation of DCs is critical for the induction of antigen-
specific immunity, several strategies have been developed to further strengthen the immune 
response by introduction of immune modulating molecules or by modulation of well-
known activation pathways such as the nuclear factor-kappaB (NF-κB), mitogen activated 
protein kinase (MAPK) p38 and MAPK c-Jun N-terminal kinases (JNK) pathways (Breckpot 
& Escors 2009a). Although LVs inherently activate DCs, they have also been evaluated for 
their ability to switch of the stimulatory capacity of DCs, thus to generate tolerogenic DCs. 
The strategies exploited therefore are similar to the strategies employed to activate DCs and 
include introduction of single inhibitory molecules and modulation of pathways that 
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regulate the tolerogenic potential of DCs, such as the MAPK extracellular signal-regulated 
kinase (ERK) pathway (Arce et al. ; Gould & Favorov 2003).   
In the remainder of this chapter, we will give a comprehensive overview on how DCs have 
evolved to the cell type of choice for manipulation of the immune system, why LVs are 
successful for the genetic modification of DCs and which developments have led to the use 
of LVs to generate stimulatory or tolerogenic DCs. We will further touch upon the concerns 
that are raised in terms of translating the use of LVs to the clinic, i.e. the biosafety of LVs, 
summarizing strategies to avoid off-target transduction, and linked herewith insertional 
mutagenesis. Finally, we will conclude this chapter with our view on the future perspectives 
for the use of LVs to manipulate DCs, hence the immune system. 
2. Dendritic cells 
Dendritic cells (DCs) as we know them today were described during the mid 1970s by Ralph 
Steinman and co-workers as a rare subset of accessory cells, which are characterized by 
stellate cytoplasmatic protrusions. It was this tree-like morphology that led to their name 
(Dendron is Greek for tree) (Steinman & Cohn 1973). DCs are a heterogeneous population 
for which individual DC subtypes have been described. These DC subtypes differ in tissue 
distribution, surface marker expression and their capacity to stimulate T cells (Palucka et al.). 
Moreover, DCs have a remarkable functional plasticity. On the one hand DCs can induce 
immune responses against invading pathogens (non-self). On the other hand DCs can 
induce T cell anergy/depletion, and regulatory T cells (Treg) to avoid unwanted immune 
reactions against auto-antigens (self) (Fig. 1). This Janus-like functional behaviour is 
correlated with complex decision-making processes, triggered by the presence or absence of 
so called danger signals, hence resulting in the expression of stimulatory and/or inhibitory 
molecules, respectively (Coquerelle & Moser). Although, we are still deciphering the DC 
system in its complexity, DCs have entered the clinic as a cellular therapeutic. 
2.1 Dendritic cell subsets 
Originally it was thought that DCs were of myeloid origin. Studies demonstrating in vitro 
generation of DCs from monocytes (Sallusto & Lanzavecchia 1994), and in vivo studies 
demonstrating the differentiation of phagocytic monocytes to DCs (Randolph et al. 1999) 
supported this idea. Later on, the existence of lymphoid DCs was evidenced (Wu et al. 1996; 
Wu et al. 1998). These CD11c+ MHC class II+ myeloid and lymphoid DC subtypes were 
afterwards termed CD8- DCs or CD8+ DCs, respectively. Together they are called 
conventional DCs (cDCs). Importantly, it was demonstrated in several in vivo studies that 
both CD8- and CD8+ DC subsets could be generated from either lymphoid (Martin et al. 
2000; Traver et al. 2000), or myeloid progenitors (Traver et al. 2000), mounting the question 
whether these subsets are really distinct or represent different developmental states. cDCs 
can be found within lymph nodes, spleen, and thymus, but not in bone marrow (Steinman & 
Cohn 1973). They are believed to cross-present antigens to T cells (den Haan & Bevan 2002), 
as such stimulate a T helper type 2 (TH2, humoral) and type 1 (TH1, cellular) immune 
response (Maldonado-Lopez et al. 1999). In humans, DCs expressing BDCA-1 (CD1c) and 
BDCA-3 (CD141) are considered the counterparts of mouse cDCs. However, these human 
DC subsets are often termed myeloid instead of conventional. Human myeloid DCs are 
characterized by their ability to produce high amounts of interleukin (IL)-12 in response to 
several stimuli (van Duin et al. 2006), thus to induce cellular immunity.   
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Fig. 1.  Schematic representation of DC subsets and their functional plasticity. Generally 
DC subsets are divided into cDCs (blue) and pDCs (grey). These DC subsets differ in tissue 
distribution, expression of PRRs, hence their ability to sense pathogens and subsequently 
stimulate appropriate T cell responses. Dependent on the stimuli these DCs encounter they 
will become tolerogenic or immunogenic, hence induce tolerance (Treg, red) or immunity 
(effector T cells, green), respectively. 
Another DC subset, the plasmacytoid DCs (pDCs) were described a decade ago (Siegal et al. 
1999). Whereas mouse pDCs express CD11c, human pDCs express low to undetectable 
levels of CD11c. Instead, human pDCs are characterized by the expression of CD4, CD45RA, 
as well as the expression of high levels of CD123 (IL-3 receptor) and the c-type lectin 
receptor BDCA2. Recently, it was described that pDCs can be further divided into 
subclasses based on the expression of CD2 (Matsui et al. 2009). pDCs reside in the same 
tissues as cDCs, and can moreover be found in bone marrow (Nakano et al. 2001), where 
they are believed to be a precursor for cDCs (Soumelis & Liu 2006; Segura et al. 2009). 
Nonetheless, pDCs, isolated from mice and humans, are functionally distinct from cDCs. In 
their resting state, pDCs play an important role in the induction of tolerance (Martin et al. 
2002). However, pDCs are best known for the ability to produce high amounts of type I 
interferon (IFN) in response to viral infection (O'Keeffe et al. 2002; Fitzgerald-Bocarsly et al. 
2008). In fact, pDCs control the progress of a virus infection at various levels: (i) through 
non-specific blockade of viral replication by type I IFN, (ii) by promoting the maturation of 
pDCs as well as other DC subsets (Fonteneau et al. 2004), and (iii) through the specific 
stimulation of adaptive anti-viral CD8+ T cell responses (Di Pucchio et al. 2008). 
The last DC subset to be discussed, the epidermal Langerhans’ cells (LCs), was in fact 
described in 1868 by Paul Langerhans (Merad & Manz 2009), almost a century before the 
description of cDCs (Steinman & Cohn 1973). LCs are characterized by the expression of 
Langerin and Birbeck granules. Furthermore, they are characterized by their long life span 
(weeks) when compared to other DC types (3-10 days) (Kamath et al. 2002). Upon activation 
LCs migrate through the dermis into regional lymph nodes to present antigens to T cells 
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(Romani et al. 2003). Because of this migration they are categorized as migratory DCs, a 
category, which also comprises other non-lymphoid tissue residing DCs, amongst which 
dermal DCs. LCs and dermal DCs are often grouped as skin DCs. It is generally accepted 
that these have a potent T cell stimulatory capacity (Romani et al. 2003; Larregina & Falo 
2005; He et al. 2006). Nevertheless, as for pDCs and cDCs, a possible tolerogenic capacity has 
been reported for skin DCs (Grabbe et al. 1995; Kaplan et al. 2005).  
2.2 Dendritic cells and the regulation of immune responses  
In addition to subsets with functional specialization, DCs are endowed with a remarkable 
functional plasticity. The hypothesis is that distinct DC activation stages play a role in the 
induction of tolerance versus immunity. This is correlated with the two-signal model of T cell 
stimulation, in which it is proposed that a productive T cell response requires recognition of 
MHC/peptide complexes by the T cell receptor (TCR) (signal 1) along with signalling 
through co-stimulatory molecules (signal 2). Indeed, steady-state cDCs and pDCs, have 
been described to induce T cell tolerance (Jonuleit et al. 2001; Mahnke et al. 2002; Martin et al. 
2002), whereas both activated DC types have been shown to induce immunity (Salio et al. 
2003; Cerundolo et al. 2004; Salio et al. 2004). 
Immature DCs efficiently take up pathogens, apoptotic cells and particulate antigens from the 
environment by phagocytosis, macropinocytosis, or endocytosis; process these but are 
considered inefficient in presenting these to T cells (Wilson et al. 2004). Hence, immature DCs 
are believed to induce tolerance (Steinbrink et al. 1997; Lutz & Schuler 2002). Indeed, in steady-
state conditions DCs remain immature and tissue-resident, express small amounts of MHC 
and co-stimulatory molecules hence induce T cell anergy instead of T cell activation upon DC-
T cell interaction (Hawiger et al. 2001). Furthermore, injection of immature DCs in humans 
induces tolerance (Dhodapkar et al. 2001; Jonuleit et al. 2001; Dhodapkar & Steinman 2002). In 
contrast, activated DCs are considered to be immunogenic. Maturation of DCs can be induced 
by a variety of signals, such as microorganisms (Rescigno et al. 2000; Beyer et al. 2001), 
cytokines (Jonuleit et al. 1997), interaction with CD4+ TH cells (Caux et al. 1994; Mackey et al. 
1998a; Mackey et al. 1998b) and chemicals like haptens (Aiba et al. 1997; Aiba & Tagami 1998; 
Aiba & Tagami 1999). DC maturation is associated with several coordinated events, including: 
(i) loss of endocytic and phagocytic receptors; (ii) changes in morphology; (iii) up-regulation of 
MHC and co-stimulatory molecules, such as CD40, CD80 and CD86, adhesion molecules and 
chemokine receptors, such as CCR7 (Tuyaerts et al. 2007a). The latter is one of the first changes 
and enables DCs to migrate from the periphery to the T cell areas of draining lymphoid organs 
(Forster et al. 2008). Here DCs present antigenic peptides in the context of MHC molecules to T 
cells. The phenotypic changes, high expression of antigen presenting, co-stimulatory and 
adhesion molecules, make mature DCs potent inducers of T cell immunity. However, the view 
that immature DCs induce tolerance and mature DCs induce immunity is simplified. It has 
been demonstrated that mature DCs can contribute to T cell tolerance through the induction of 
Treg (Verhasselt et al. 2004). It was suggested that the maturation trigger dictates the T cell 
polarizing or tolerating immune functions of the DCs. Some stimuli have been demonstrated 
to promote induction of TH1 responses, hence cellular immunity, whereas others hamper full 
DC maturation and cytokine production, hence promote tolerance.   
2.3 Stimulatory dendritic cells  
The immune system is constantly faced with choices. When confronted with a microbe, it 
must first decide whether to respond or not. If it chooses to respond, then it must decide 
www.intechopen.com
 Dendritic Cells and Lentiviral Vectors: Mapping the Way to Successful Immunotherapy 
 
313 
what kind of response to launch. A hallmark of the mammalian immune system is its ability 
to launch qualitatively distinct types of responses against different pathogens (Pulendran et 
al. 2008). Immune responses against T cell-dependent antigens can be divided in (i) CD4+ 
TH1 responses, which are characterized by high secretion of IFN-γ, and induced against 
intracellular microbes, (ii) CD4+ TH2 responses, which are characterized by the secretion of 
cytokines, such as IL-5 and IL-13, and induced against extracellular pathogens, (iii) CD4+ 
TH17 responses, characterized by the secretion of IL-17, and induced against fungi (Bettelli et 
al. 2007; Reiner 2007), and finally (iv) Treg responses, with suppressive activity, and which 
are essential to maintain tolerance to host antigens (Wing & Sakaguchi). Treg can also be 
induced by some microbial stimuli (Belkaid 2007), and are abundantly present in the blood, 
lymphoid organs and tumours of cancer patients (Vence et al. 2007; Ahmadzadeh et al. 2008), 
as such Treg enable evasion from the immune system.   
For the treatment of cancer and infectious diseases, a CD4+ TH1 response is required to 
induce a strong CD8+ cytotoxic T cell (CTL) response (Breckpot & Escors 2009a). These CTLs 
will then kill the target cells. To activate T cells, at least two signals are required (i) antigen 
recognition and (ii) co-stimulation. In the presence of tolerogenic mechanisms, as it is the 
case in cancer, an additional third signal is required. This is obtained by triggering of innate 
sensing pathways (Breckpot & Escors 2009a). As co-stimulatory molecules are not expressed 
by immature DCs, it goes without saying that DC activation (maturation) is a key event that 
determines the T cell stimulatory potential of DCs.  
Differentiation of immature to mature DCs requires pathogen recognition. Groups of 
pathogens express similar structures such as bacterial and viral nucleic acids or repetitive 
elements in the bacterial cell wall or within the viral envelope, enabling the recognition of a 
wide variety of pathogens. These structures are called pathogen-associated molecular patterns 
(PAMPs) and are recognized on DCs by pathogen recognition receptors (PRRs). The best-
studied PRRs are the TLRs, although other PRRs, such as Nod-like receptors, RIG-I-like 
receptors, as well as some members of the C-type lectin family, are described. Distinct 
pathogens express different PAMPs and this combination works as a fingerprint that triggers a 
specific set of PRRs (Akira et al. 2006; Barton & Kagan 2009; Geijtenbeek & Gringhuis 2009). As 
such complex signalling networks are activated. These cooperate, integrate and finally 
converge into a few pathways, of which the NF-κB and the MAPK pathways are examples 
(Rescigno et al. 1998; Sato et al. 1999; Re & Strominger 2001; Caparros et al. 2006; Kawai & Akira 
2008). These are described in detail elsewhere (Breckpot & Escors 2009c).  
The concept of co-stimulation was first introduced by Kevin Lafferty and co-workers 
(Lafferty et al. 1979). In the last decades, a large number of co-stimulatory molecules have 
been identified, which can be divided in members of the (i) B7 and (ii) tumour necrosis 
factor (TNF) type family. B7.1 (CD80) and B7.2 (CD86) are textbook examples of the B7 
family. These transmit strong co-stimulatory signals to T cells through interactions with 
CD28 on T cells (Greenwald et al. 2005). Recently, this group was expanded with a number 
of new members including ICOS ligand, PD-L1 (B7-H1), PD-L2 (B7-DC), B7-H3 and B7-H4. 
All these molecules are expressed on DCs. The corresponding CD28 members that are 
inducible expressed on T cells are ICOS, PD-1 and BTLA. It is important to mention that not 
all B7 family members are co-stimulatory. In fact, many of these new members have been 
linked to induction of tolerance hence they are discussed in the next section. The TNF type 
family of co-stimulatory molecules, includes CD70, OX40L, GITRL and 4-1BBL, which are 
expressed on DCs and their corresponding receptors CD27, OX40 (CD134), GITR and 4-1BB 
(CD137), expressed on T cells (Watts 2005). Some co-stimulatory molecules exemplified by 
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CD83, which is expressed on mature DCs, but also on T cells, can’t be classified in either 
group. So far, no receptor has been identified for this molecule (Hirano et al. 2006; Aerts-
Toegaert et al. 2007; Prechtel et al. 2007).   
Initial activation of naive T cells generally occurs through interactions with CD28, after 
which they differentiate into effector T cells, and up-regulate other co-stimulatory 
molecules. Depending on the stimulus, expression of co-stimulatory ligands on DCs will 
vary. Their relative expression will ultimately determine the quality of the T cell stimulation 
hence the T cell function. It has to be mentioned that the importance of co-stimulatory 
molecules is not limited to the stimulation of effector T cells, but can moreover involve 
modulation of Treg, as described for GITRL and OX40L. It has been shown that triggering of 
GITR results in alleviation of Treg suppression of effector T cells. Although Treg 
constitutively express GITR, the effect of GITR-GITRL interactions is not mediated through 
functional impairment of Treg, but rather protection of effector T cells against Treg 
(Stephens et al. 2004). However, whether these observations in mice can be translated to a 
human setting remains unclear (Tuyaerts et al. 2007b). Direct inhibitory effects on Treg 
suppression have been shown for OX40L (Valzasina et al. 2005), which upon binding with 
OX40 on Treg mediates down-regulation of Foxp3 and the Tregs’ suppressive capacity (Vu 
et al. 2007). For other co-stimulatory molecules (CD70 and 4-1BBL), of which its receptors are 
also expressed on Treg, no unequivocal effect on Treg function has been described.  
2.4 Tolerogenic dendritic cells  
In physiological conditions, the organism is in direct contact with millions of innocuous 
antigens of different origins.  Many of them are bacterial antigens, such as those present 
within the gut. Others vary from pollen, yeast, dust mites and chemicals of all sorts. Until 
recently, it was thought that the immune system was constantly and restlessly fighting 
potentially dangerous organisms and antigens. This view has certainly become obsolete, and 
it is not inaccurate to consider the immune system in a kind of steady-state in which 
tolerance is the default outcome and has to be maintained at all costs, except when a real 
threat arises. Therefore, several tolerogenic mechanisms are constantly in place.   
One of the first mechanisms to be described is central tolerance, in which auto-reactive T 
cells are eliminated in the thymus by clonal deletion (Griesemer et al. 2010). Although this 
mechanism is essential to eliminate most auto-reactive T cells, it can’t explain the aetiology 
of autoimmune disorders in which self-antigens are clearly recognised. Even though clonal 
deletion is efficient, it does not eliminate all auto-reactive T cells. Interestingly, many auto-
reactive T cells that survive clonal deletion further differentiate into natural Foxp3+ CD4+ 
Treg (Sakaguchi et al. 2008; Griesemer et al. 2010). These are strong and intrinsic 
immunosuppressive, and are part of the central tolerance. Research on Treg has recently 
exploded, although ample experimental evidence of their existence was provided during the 
1970s (Rich & Pierce 1973; Ha et al. 1974; Taussig 1974). However, early studies were 
abandoned partly by the inexistence of specific cell markers associated with suppressive T 
cells. Nevertheless, Sakaguchi and colleagues demonstrated that high expression of CD25 
and Foxp3 was characteristic for natural Treg (Hori et al. 2003; Sakaguchi 2003), which re-
awakened research into this fundamental T cell type. Importantly, many of the early studies 
drew similar conclusions to more recent studies on Treg (Basten et al. 1974; Kirchner et al. 
1974; Polak & Turk 1974). Even so, clonal deletion and natural Treg activity can’t explain 
tolerance towards many other auto- and foreign antigens, which are not present in the 
thymus. Theoretically strong immune responses should constantly arise towards a wide 
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variety of antigens. However, this is not the case, and the organism still remains tolerant 
towards most antigens. Differentiation of inducible Treg specific for peripheral antigens can 
partially fill this experimental and conceptual gap. Inducible Treg derive from naïve CD4+ T 
cells and can be broadly classified into Tr1 (CD4+ CD25+ IL-10+ or TGF-β+) and TH3 (CD4+ 
CD25+ Foxp3+) cells (Mahnke et al. 2003; O'Garra et al. 2004; Peng et al. 2004; Arce et al. 2011). 
For differentiation of inducible Treg to occur, antigens have to be captured, processed and 
presented in a tolerogenic context. DCs, which induce Treg differentiation and inhibition of 
effector T cell expansion, are termed tolerogenic DCs.  
There is no compelling evidence demonstrating that tolerogenic DCs are a truly specialised cell 
type that is exclusively devoted to suppress immune responses. In fact, tolerogenic DCs 
encompass a wide range of DCs which acquire immune suppressive activities in particular 
circumstances. Firstly, it is well known that steady state DCs can capture antigens in 
peripheral tissues and migrate to secondary lymphoid organs. Antigen presentation by 
immature DCs leads to T cell inactivation (anergy), apoptosis and Treg differentiation 
(Dhodapkar et al. 2001; Hawiger et al. 2001; Bonifaz et al. 2002; Kretschmer et al. 2005). 
Secondly, DCs located in certain anatomical parts such as the mucosa and gut, are intrinsically 
tolerogenic. Interestingly, retinoic-acid (vitamin A) metabolising enzymes are critical in their 
suppressive functions. Mucosal DCs in contact with many microbial-derived antigens are 
potently immunosuppressive, particularly after TLR2 signal transduction (Dillon et al. 2006; 
Ilarregui et al. 2009; Manicassamy et al. 2009). Treatment of DCs with lectin ligands such as 
galectin 1 or potent immunosuppressive cytokines also renders them tolerogenic (Corinti et al. 
2001; Ghiringhelli et al. 2005; Dillon et al. 2006; Rutella et al. 2006; Ilarregui et al. 2009; Arce et al. 
2011). Importantly, certain types of specialised myeloid-derived cells with very potent intrinsic 
immunosuppressive capacities have been found in recent years. These cells are known as 
myeloid-derived suppressor cells and inhibit T cell proliferation through a variety of 
mechanisms (Li et al. 2009; Srivastava et al. 2010). In addition, certain types of monocytes are 
immunosuppressive cells, and are involved in establishing tolerance after organ 
transplantation (Garcia et al. 2010). According to the expression of surface molecules, 
tolerogenic DCs are generally considered to be immature. This is characterised by low levels of 
MHC and co-stimulatory molecules (Rutella et al. 2006; Escors et al. 2008; Breckpot & Escors 
2009b; Arce et al. 2010). It is believed that because of their immature phenotype antigen 
presentation is inefficient, and expansion of effector T cells is hampered. However, 
phenotypical mature DCs can also be potently tolerogenic. These mature tolerogenic DCs exert 
their suppressive activities through secretion of high levels of immunosuppressive cytokines 
(Rutella et al. 2006).  
The mechanisms by which tolerogenic DCs exert their activity are certainly varied in nature, 
and it is likely that several of these take place simultaneously. As mentioned, tolerogenic 
immature DCs are thought to lead to inefficient antigen presentation to naive T cells. 
Therefore, expansion of effector T cells is, if not prevented, at least severely reduced. However, 
there is evidence that these DCs do present antigens, although the interaction between 
immature DCs and T cells is transient and leads to T cell anergy, apoptosis or Treg 
differentiation (Rothoeft et al. 2006). An important characteristic that seems to be common in 
all tolerogenic DCs is the secretion of potent immunosuppressive cytokines during antigen 
presentation (Ghiringhelli et al. 2005; Dillon et al. 2006; Escors et al. 2008; Ilarregui et al. 2009; 
Arce et al. 2010; Saraiva & O'Garra 2010). In fact, at least in the presence of TGF-β, strong TCR 
stimulation during antigen presentation greatly enhances Foxp3+ Treg differentiation. 
Tolerogenic DCs can also secrete high amounts of IL-10, a potent immunosuppressive 
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cytokine, resulting in differentiation of mainly Tr1 cells (Kuhn et al. 1993; Saraiva & O'Garra 
2010). In addition IL-10 autocrine and paracrine activities keep DCs in an immature stage 
(Takayama et al. 1998; Corinti et al. 2001). DCs can also up-regulate surface expression of 
molecules with T cell inhibitory activities. This is the case for some members of the B7 family. 
One of the most extensively studied immunosuppressive members is PD-L1, the ligand of the 
T cell inhibitory receptor PD-1. Binding of PD-L1 to PD-1 on T cells, especially in the case of 
chronic antigen exposure, renders T cells inactive (exhausted) (Sakuishi et al. 2010). This is a 
critical mechanism by which many tumour cells exert their immunosuppressive activities 
towards effector CD8+ T cells. PD-L1 is expressed ubiquitously, but it is likely that its 
expression on DCs and other professional antigen presenting cells has a more specific role. 
Importantly, binding of PD-L1 expressed on DCs to CD80 on T cells has been shown to be 
required for TGF-β dependent antigen-specific Treg differentiation (Wang et al. 2008). A 
second PD-1 ligand was described that is specifically expressed on DCs and macrophages, 
termed PD-L2. However, it is unclear whether PD-L2 is truly immunosuppressive 
(Radhakrishnan et al. 2009). Recently, other B7 family members have also been shown to exert 
immunosuppressive activities (Sica et al. 2003). Finally, another interesting mechanism is up-
regulation of amino acid-metabolising enzymes. Intriguingly, many of these are triggered by 
TGF-β (Belladonna et al. 2009). It has been known for some time that increased arginase 
activity in DCs suppresses immune responses (Munder 2009; Norian et al. 2009). Indoleamine 
2,3-dioxygenase up-regulation, a tryptophan-metabolising enzyme, suppresses immune 
responses (Fallarino et al. 2002; Mellor & Munn 2004). Interestingly, Tregs can induce DCs to 
up-regulate several of these metabolic enzymes, resulting in infectious tolerance that amplifies 
the suppressive capacities of regulatory DCs and T cells (Cobbold et al. 2009).  
3. Lentiviral vectors 
Viruses are excellent candidates for the development of efficient gene delivery systems. As 
intracellular obligate parasites, they are specialized in the delivery of their genome to cells. 
Therefore it is no surprise that viruses have always been of interest for gene therapeutic 
applications. Nowadays a large number of viruses have been evaluated, e.g. adenovirus, 
adeno-associated virus, herpes virus, poxvirus, retrovirus, lentivirus, et cetera (Escors & 
Breckpot 2010). The first human gene therapy trial was performed in the 1970s and applied an 
arginase encoding Shope papilloma virus to treat hyperargininemia (Friedmann & Roblin 
1972). By 1985, gene transfer with viral vectors to mammalian cells was performed routinely 
and the use of the γ-retroviral Murine leukaemia virus for gene delivery was introduced 
(Mann et al. 1983). This seemed promising as these viruses integrate their cargo into the host 
genome. It was Brenner et al (Brenner et al. 1993) who demonstrated the proof-of-principle of γ-
retroviral gene transfer in hematopoietic stem cells (HSCs). The first clinical trial using γ-
retroviral vectors (RVs) was carried out by Anderson and colleagues to correct severe 
combined immunodeficiency (SCID) in 1991 (Anderson et al. 1990). The majority of clinical 
gene therapy trials today use γ-RVs, despite their relative low stability, the low titers and their 
inability to transduce quiescent cells. More importantly, worrisome incidents of RV induced 
insertional mutagenesis were reported (Pincha et al. 2010).  Lentiviruses, which as γ-
retroviruses are members of the Retroviridae, were suggested to be an attractive alternative, 
since they are capable of transducing both dividing and non-dividing cells (Bukrinsky et al. 
1993; Lewis & Emerman 1994). Moreover, their integration into the host genome is, in contrast 
to γ-retroviruses, associated with lower genotoxicity (Montini et al. 2006). 
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At the end of the 1990s, the use of recombinant LVs was boosted, especially for transduction 
of non-dividing cells (Akkina et al. 1996; Naldini et al. 1996a; Naldini et al. 1996b; Reiser et al. 
1996).  Another 10 years later the first clinical trial using LV modified cells for the treatment 
of HIV infection was completed (Lu et al. 2004). 
3.1 Development of recombinant lentiviral vectors  
Lentiviruses are characterized by a diploid 7-12 kb single stranded RNA genome with 
positive polarity that is reverse transcribed to double stranded DNA upon host cell entry 
(Coffin 1997).  Diploidy permits genetic recombination, which accounts partially for their 
success as procreators of the acquired immunodeficiency syndrome, a disease that develops 
by slowly affecting the immune systems’ function (lenti meaning slow).  Lentiviruses 
include primate and non-primate retroviruses, e.g. HIV and simian immunodeficiency virus, 
and caprine arthritis-encephalitis virus, equine infectious anaemia virus, Maedi-visna virus, 
feline immunodeficiency virus and bovine immunodeficiency virus, respectively (Breckpot 
et al. 2008; Escors & Breckpot 2010).  The spherical virion measures about 80-120 nm in 
diameter, has a mass of 2.5 x 105 kDA and a density of 1.16 g/ml in sucrose density gradient. 
Its envelope consists of a plasma membrane derived phospholipid bilayer loaded with 
surface (SU) and transmembranary (TM) glycoproteins and is supported on the inside by 
the non-glycosylated structural matrix (MA) proteins (Fig. 2). Within the envelope the 
nucleocapsid, comprised of capsid (CA) proteins, surrounds the viral genome, which is 
packaged together with nucleocapsid (NC) proteins and a few copies of the enzymes reverse 
transcriptase (RT), integrase (IN) and protease (PR). 
 
 
Fig. 2. Schematic representation of a retroviral particle. The viral envelope consists of a 
lipid bilayer loaded with viral proteins. These are composed of TM and SU components, 
linked via a disulphide bridge and encoded by de env genes. Internal non-glycosylated 
proteins are coded by the gag region of the viral genome and comprise MA, CA and NC 
proteins. The products of the pol – coding region are the RT and IN, while the PR is coded by 
the pro gene that resides between the gag and the pol gene. 
The replication cycle of lentiviruses starts with the attachment of the viral envelope proteins to 
specific receptors on the host cell surface (Flint S.J. 2009). This interaction defines the tropism 
and results in conformational changes of SU and TM, which allows the hydrophobic fusion 
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peptide of TM to insert in the cellular membrane, as such allowing the release of the 
nucleocapsid complex in the cytoplasm (Schaffer et al. 2008). The reverse transcription process 
sets off by primer binding of a viral tRNA and produces successively the negative and positive 
linear DNA strands till the DNA molecule called provirus is formed. Important are its cis-
acting ends called long terminal repeats (LTRs) that are shown juxtaposed in preparation for 
integration (Fig. 3). As a unique characteristic of lentiviruses, viral DNA and IN gain access to 
the nucleus by formation of a pre-integration complex. Therefore, the lentiviral genome 
contains not only a 3’ polypurine tract (PPT), as other retroviruses, but also a central PPT (Fig. 
3) (Charneau & Clavel 1991). The latter sequence together with a central termination sequence 
(CTS) controls the formation of a stable 99-nucleotide long plus strand overlap in the linear 
DNA molecule in cis, which enables active pro-viral nuclear import (Follenzi et al. 2000; 
Zennou et al. 2000). The subsequent integrative recombination is catalyzed by the IN, which 
uses the outer att sequences on the LTRs to grab the pro-viral DNA and results in random 
insertion of the viral DNA in the host genome. Transcription of the integrated provirus is 
mediated by cellular RNA polymerase II and results in different subsets of RNA molecules 
namely: mRNA molecules and new viral single stranded RNA genomes. The most important 
viral genes encoding mRNA molecules are: (i) the env (envelope) gene which encodes SU and 
TM; (ii) the gag (group specific antigen) gene which encodes the internal structural proteins MA, 
CA and NC; (iii) the pol (polymerase) gene which codes for the enzymes IN and RT including a 
DNA polymerase as well as its associated RNase H activity and finally (iv) the pro (protease) 
gene which encodes PR. Based on genomic organization retroviruses can be divided in simple 
and complex viruses. The simple viral genomes only encode the three genes, gag, pol, and env, 
common to all retroviruses, such as α-, β-, and γ-retroviruses. In contrast, complex viruses have 
a genome that encodes several accessory genes that affect viral gene expression and/or 
pathogenesis. Lentiviruses encode not only two extra regulatory genes tat and rev but also 
several accessory genes such as vpr, vpu, vif and nef.  After transcription of the unspliced full-
length viral RNA and translation of the mRNA encoding viral proteins, everything is 
transported to the cytoplasm where virion maturation occurs.  The cis-acting packaging signal, 
ψ (psi), is required to ensure viral genome packaging and subsequent budding of the particle 
from the cell to give rise to infectious virions. 
 
 
Fig. 3. Schematic representation of the pro-viral HIV-1 genome. All genes of the provirus 
(gag, pol, pro, vif, vpr, vpu, rev, tat, env and nef) are flanked on either side by identical ‘long 
terminal repeats’ (LTRs) that consist of a U3, R and U5 fragment. The pro-viral 
transcriptional control elements like the actual promoter and enhancer sequences can be 
found in the U3 regions. Ψ represents the encapsidation signal. Unlike most retroviruses, 
HIV and other LVs have two copies of the PPT, one at the border of the 3’LTR (3’ polypurine 
tract) and the other located within the pol-coding region (central polypurine tract [red line] 
together with a central termination sequence [green line]). 
Given the fact that lentiviruses are pathogenic, it is crucial to develop a recombinant LV that is 
replication deficient, safe and efficient in transduction of target cells. Therefore, LVs have been 
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vigorously modified, which has contributed to their widespread use as a gene delivery shuttle. 
A safety concern is the possible generation of replication-competent LVs (RCLs) as a 
consequence of genetic recombination (Wu et al. 2000). Therefore, LVs are produced by 
transient transfection of producer cells (HEK 293T) with at least three plasmids. This allows 
separation of cis- and trans-acting sequences. Generally the following plasmids are used: (i) a 
packaging, (ii) a transfer, and (iii) an envelope plasmid. All plasmids have been scrutinized to 
enhance their performance in terms of safety and efficacy (Breckpot et al. 2007a).   
The packaging plasmid provides all viral structural and enzymatic sequences, encoded by 
gag and pol, to make an infective virion in trans. Based on the packaging plasmid 
recombinant LVs can be divided into different generations. The first generation is 
represented by a plasmid encoding the entire gag and pol sequence in trans to enable 
packaging of the transfer construct together with the viral regulatory genes tat and rev and 
the virulence genes vif, vpr, vpu and nef. The second generation plasmid is multiply 
attenuated by removal of the four virulence genes without any negative effect on 
transduction efficacy as these genes seemed dispensable for the efficient generation of HIV-
derived LVs (Zufferey et al. 1997). In the third generation, the rev gene is expressed from a 
separate plasmid (Dull et al. 1998). Furthermore also the tat sequence could be removed by 
insertion of a strong constitutional promoter in the 5’ LTR of the transfer vector. More 
recently the importance of the development of non-integrating LVs (NILVs) has been 
brought to the attention because of the oncogene transactivation incidents in some clinical 
trials with γ-RVs. Although the LV integration profile seems more favourable than that of γ-
RVs (Montini et al. 2009), several groups tested the transduction efficacy of NILVs by 
mutating the catalytic triad within the IN gene of the packaging plasmid (Wanisch & Yanez-
Munoz 2009). Improved safety without major reduction in efficacy was demonstrated (Negri 
et al. 2007; Karwacz et al. 2009; Wanisch & Yanez-Munoz 2009). Downsides are the lower 
titers, higher doses needed and the fact that there still is a chance for integration of about 0.1 
to 2.3% (Apolonia et al. 2007). An alternative to IN deficiency is site-specific integration into 
a safe harbour sequence of the target cell. Several strategies have been described, e.g. Cre-
loxP carrying LVs, use of the zinc finger nuclease or meganuclease technology, et cetera 
(Matrai et al. 2010; Michel et al. 2010; Silva et al. 2011). Furthermore, the discovery that the 
LEDGF/p75 protein controls the site of integration of HIV-derived LVs presents new 
possibilities to control mutagenesis (Ciuffi 2008; Silvers et al. 2010). 
The transfer plasmid is the only plasmid derived from the viral genome where all viral 
coding regions are replaced by the expression cassette. An important improvement for 
safety was the development of so called self-inactivating (SIN) vectors (Zufferey et al. 1998). 
These rely on the introduction of a deletion in the U3 region of the 3’ LTR.  This deletion will 
be transferred to the 5’ LTR of the pro-viral DNA during reverse transcription, which 
abolishes production of full-length vector RNA in transduced cells. This has several 
advantages: (i) it minimizes the risk for emerging RCLs, (ii) it reduces the chance that 
cellular coding sequences located adjacent to the integrated pro-viral sequence will be 
aberrantly expressed due to the promoter activity in the 3’ LTR and (iii) it prevents 
transcriptional interference between the LTRs and an internal promoter. As the expression 
of genes delivered by LVs is often inefficient, several strategies were developed to 
ameliorate this. Firstly, the promoter within the expression cassette can be varied. Instead of 
using strong constitutive promoters, such as the promoter of cytomegalovirus or spleen 
focus forming virus, one can choose a cell-specific promoter as these are less sensitive to 
promoter inactivation and less likely to activate the host-cell defence machinery (Liu et al. 
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2004). Secondly, the incorporation of the cPPT and CTS into the transfer plasmid not only 
improved LV yields, but also provided enhanced transgene expression by mediating active 
nuclear import of the provirus (Follenzi et al. 2000; Sirven et al. 2000). Addition of 
posttranscriptional regulatory elements such as the Woodchuck hepatitis virus regulatory 
element (WPRE) has also been explored (Zufferey et al. 1999). Although some groups 
demonstrated improved gene expression by modification of polyadenylation, RNA export 
and/or translation, others reported only a negligible benefit (Breckpot et al. 2003). Another 
issue is epigenetic silencing and heterochromatin formation nearby the inserted provirus, 
which hampers its transcription. This silencing process can be avoided by the insertion of 
insulators or with vectors containing an enhancer-less ubiquitously acting chromatin-
opening element (Zhang et al. 2007; Nielsen et al. 2009). To improve safety, the incorporation 
of a suicide-gene has been proposed to eliminate cells that are transformed as a consequence 
of LV integration (Tseng et al. 2009). Finally the discovery of RNA interference opens novel 
possibilities for LVs in terms of stable gene silencing (Gu et al. ; Arrighi et al. 2004), as well as 
for LV de-targeting strategies (Brown et al. 2006b). 
Last but not least also the envelope plasmid is variable. Since wild-type HIV-1 glycoproteins 
have a restricted tropism and do not allow production of high titer LV preparations, 
heterologous glycoproteins are used for LV production. This process is termed 
pseudotyping and most commonly the envelope of the vesicular stomatitis virus (VSV.G) is 
used. This rhabdovirus envelope glycoprotein interacts with an ubiquitous receptor and 
subsequently confers a broad host-cell range and high vector particle stability (Burns et al. 
1993; Marsac et al. 2002; Schaffer et al. 2008). 
3.2 Lentiviral vectors for the in vitro modification of dendritic cells  
Efficient transduction of human DCs with transgenic vectors has been challenging for 
several reasons.  Human DCs are usually generated from peripheral blood-derived 
quiescent CD14+ progenitors or from mitotically hypoactive primitive CD34+-derived 
progenitor cells. Therefore, the capacity of LVs to transduce quiescent and non-dividing 
cells turned out to be an important asset for DC transduction. The first successful 
transduction of human monocyte-derived DCs with LVs was described by Unutmaz et al 
(Unutmaz et al. 1999) in 1999. Since then, several research groups have reported successful 
transduction of human monocyte-derived (Gruber et al. 2000; Schroers et al. 2000; Dyall et al. 
2001; Firat et al. 2002; Breckpot et al. 2003; Lizee et al. 2004), human CD34+-derived DCs 
(Salmon et al. 2000; Oki et al. 2001; Sumimoto et al. 2002) and mouse bone marrow-derived 
DCs (Metharom et al. 2001; Breckpot et al. 2003) with varying efficiencies. Transgene 
expression was found to be stable in monocyte-derived DCs (Gruber et al. 2000; Breckpot et 
al. 2003) and CD34+-derived DCs (Oki et al. 2001). However, for mouse DCs, the kinetics are 
somewhat more complicated, due to a process which is called pseudotransduction (Dullaers 
et al. 2004), and which results in a wrong estimation of the transduction efficiency when 
analyzed early after transduction. Nevertheless, DCs can be modified at high efficiency 
(Breckpot et al. 2003). Importantly, there is quite some variability in transduction efficiency 
among different reports. This most likely reflects the diversity in DC sources, techniques 
and vectors used for transduction (Breckpot et al. 2004a). 
3.3 Lentiviral vectors for the in vivo modification of dendritic cells  
As broad-tropism LVs efficiently transduced mouse and human DCs in vitro, it was next 
questioned whether these LVs can be used to transduce DCs in vivo, as such circumvent the 
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labour-intensive, time- and money-consuming procedure of generating DCs ex vivo. 
Dullaers et al (Dullaers et al. 2006) used a PCR-based method to demonstrate the presence of 
the LV delivered transgene in the draining lymph node at days 2 and 10, but not day 25 post 
administration of LVs in the footpad. These data were confirmed in flow cytometry, 
demonstrating that the PCR signal correlated with a small percentage (less than 1%) of 
transduced CD11c+ cells (unpublished data Dullaers et al).  Using the same injection route, 
Esslinger et al (Esslinger et al. 2003) showed transduction of CD11c+ cells in the lymph node 
by immunohistochemical analysis, whereas He et al (He & Falo 2006) were able to 
demonstrate by flow cytometry that transduced DCs present in the lymph node after 
footpad injection of GFP encoding LVs originated from locally transduced migratory skin 
DC. More recently, a new imaging technique, in vivo bioluminescence imaging, was used to 
visualize cells transduced in situ with Firefly luciferase encoding LVs upon footpad injection 
(Breckpot et al.). Intravenous administration of LVs also leads to transduction of DCs in the 
spleen (VandenDriessche et al. 2002; Palmowski et al. 2004; Arce et al. 2009). These studies 
indicate that LVs, independent of the route of administration transduce DCs in situ and have 
instigated the exploration of LVs as an off-the-shelf vaccine. 
4. Exploitation of lentivirally transduced dendritic cells in anti-cancer 
immunotherapy 
Active anti-tumour immunotherapy is based on the delivery of tumour antigens (Boon & 
van der Bruggen 1996) in a way that induces therapeutic immunity. As several tumour-
induced tolerogenic mechanisms are in place it is not sufficient to stimulate effector T cells, 
it is moreover critical to circumvent suppressive immune cells, such as Treg.  Such anti-
tumour immunity can only be induced by professional antigen presenting cells, in particular 
DCs, and requires presentation of the tumour antigen-derived peptides to both CD4+ and 
CD8+ T cells in the context of strong co-stimulation. As mentioned previously LVs have 
been tested as vehicles, for ex vivo and in vivo antigen delivery to DCs.  In the following 
section we will discus the induction of potent T cell mediated immune responses that can 
control tumour growth by ex vivo, as well as in situ LV transduced DCs.  Finally, we will 
discuss some strategies that have been explored to enhance the performance of LV-based 
vaccines. 
4.1 Evaluation of ex vivo lentiviral vector transduced dendritic cells as a cellular anti-
tumour vaccine 
Since the beginning of the millennium, several reports on the use of tumour antigen 
encoding LVs for the ex vivo modification of DCs have been published.  As it is of 
paramount importance that tumour antigen-derived peptides are efficiently processed and 
presented on the DC surface in order to efficiently prime and activate tumour antigen-
specific T cells, it was first evaluated whether LV transduced DCs activate established T cell 
lines.  Note, strategies in which the tumour antigen encoding genetic sequence is fused to 
the sequence encoding class II targeting signals, such as the first 80 amino acids of the 
invariant chain (Ii80), were employed to obtain not only presentation of antigenic peptides 
in MHC class I, but furthermore in MHC class II in order to activate CD8+ and CD4+ T cells, 
respectively (Bonehill et al. 2005).  As mentioned before, the activation of IFN-γ producing 
CD4+ TH1 cells supports priming and maintenance of CTLs, moreover in anti-tumour 
immunotherapy, it has been shown that these CD4+ TH1 cells mediate tumour rejection 
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(Bonehill et al. 2003). Both human and mouse LV transduced DCs were able to activate 
established CD8+ and CD4+ T cell lines specific for epitopes derived from various relevant 
tumour antigens, such as MAGE-3 (Breckpot et al. 2003), Melan-A (Firat et al. 2002; 
Sumimoto et al. 2002) and tyrosinase (Lizee et al. 2004) in the human system and for the 
surrogate antigen ovalbumin (OVA) (Breckpot et al. 2003; He et al. 2005), as well as for TRP-2 
(Metharom et al. 2001) in the murine system.  
Moreover, several groups reported on the in vitro priming of naive T cells against tumour 
antigens using LV transduced human DCs. Firat et al (Firat et al. 2002) stimulated CD8+ T 
cells in bulk with monocyte-derived DCs that were transduced with LVs encoding a 
melanoma poly-epitope and demonstrated expansion of tetramer+ CD8+ T cells, which 
could specifically lyse gp100 and Melan-A peptide-pulsed targets. We showed priming of 
both CD8+ and CD4+ T cells against the poorly immunogenic melanoma antigen MAGE-
A3 after in vitro stimulation with DCs transduced with LVs encoding the fusion protein 
Ii80MAGEA3 (Breckpot et al. 2003). The primed CD8+ T cells were further cloned and 
characterized enabling the identification of a novel HLA-Cw7 restricted MAGE-A3 
peptide (Breckpot et al. 2004b). A number of groups evaluated the potential of mouse DCs 
transduced with LVs as a cellular anti-tumour vaccine in vivo.  Herein, the induced 
immune response was characterized and tested for protection against tumour growth. We 
showed that immunization with DCs transduced with OVA encoding LVs induced a 
strong CTL response, resulting in specific lyses of OVA-expressing tumour cells after in 
vitro restimulation (Breckpot et al. 2003) or in vivo upon delivery of autologous OVA 
peptide-pulsed spleen cells (Dullaers et al. 2006). He et al (He et al. 2005) confirmed these 
data. It was moreover demonstrated that these CTL responses were protective against a 
subsequent challenge with a lethal dose of OVA-expressing B16 melanoma cells and 
slowed down the outgrowth of pre-existing tumours (He et al. 2005; Dullaers et al. 2006). 
Later on, it was shown with endogenous tumour antigens that the results obtained with 
the strong immunogenic OVA were not an overestimation of the potential of LV 
transduced DCs as a cellular therapeutic. Tumour antigens such as TRP-2 (Metharom et al. 
2001) and erbB2 (mouse analogue of human Her-2/neu) (Mossoba et al. 2008) were used 
to demonstrate induction of strong CTL responses and decreased tumour growth. 
Importantly, Wang et al. (Wang et al. 2006) extended these data in a mouse hepatoma 
model, immunized with LV transduced DCs expressing three hepatoma-associated 
antigens, which are self-antigens that are highly expressed in tumour cells, demonstrating 
CD4+ and CD8+ T cell responses against all three hepatoma antigens, as well as regression 
of established tumours.  Delivery of multiple tumour antigens might overcome the 
problem of tumour escape due to antigen loss (Dullaers et al. 2006). Finally, it has to be 
noted that several groups compared DCs transduced with LVs to DCs pulsed with 
(tumour) antigen-derived peptides (He et al. 2005; Metharom et al. 2005) or electroporated 
with mRNA (Dullaers et al. 2004), two strategies that were approved in the clinic, 
demonstrating that LV modified DCs elicited stronger and longer-lasting anti-tumour T 
cell responses.  
These studies suggest that ex vivo LV transduced DCs are effective in therapeutic treatment 
of cancer.  However, this strategy has important drawbacks common to all DC-based 
vaccination approaches. Because the vaccine is patient-specific it requires specialized 
personnel and facilities for vaccine production. Consequently, there is a high cost and 
considerable time required for vaccine production and quality control. It is for that reason 
that direct administration of LVs in vivo has gained substantial interest.  
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4.2 Evaluation of lentiviral vectors as an off-the-shelf anti-tumour vaccine 
For LVs to be an effective vaccine they have to transduce DCs in situ, a pre-requisite that 
is fulfilled.  Furthermore, the in vivo transduced DCs need to process the transgene, have 
to be activated so they migrate to lymphoid organs, where they subsequently present 
transgene-derived epitopes in the context of MHC molecules and strong co-stimulation to 
T cells. Hence, the degree of tumour antigen-specific CTL induction can be considered as 
a reliable measure for the value of direct administration of tumour antigen encoding LVs 
in tumour immunology. Antigen-specific CTLs could be generated upon direct 
administration of LVs using HLA-Cw3 as a model antigen (Esslinger et al. 2003). Similar 
results were obtained in HLA-A transgenic mice using a LV encoding a minigene 
containing the dominant human Melan-A HLA-A*0201 epitope (Chapatte et al. 2006) or 
human telomerase reverse transcriptase (hTERT) (Adotevi et al. ; Rusakiewicz et al.). 
Using OVA as an antigen, it was confirmed that direct administration of LVs resulted in a 
higher number of IFN-γ producing CD8+ T cells, which had a higher lytic capacity as 
compared to those primed with ex vivo transduced DCs (Dullaers et al. 2006). Memory 
CTL responses were also significantly stronger upon LV administration. Other studies 
with tumour antigens such as NY-ESO (Palmowski et al. 2004), TRP-2 (Kim et al. 2005), 
TRP-1 (Liu et al. 2009) and CEA (Loisel-Meyer et al. 2009), have also shown potent 
immune responses upon vaccination with LVs. Comparison of in vivo administration of 
LVs to the peptide or DNA vaccination strategy was performed in a HLA-A transgenic 
mice, by Chapatte et al (Chapatte et al. 2006) and Rusakiewicz et al (Rusakiewicz et al.), 
demonstrating that stronger tumour-specific immune responses were elicited when 
immunization was performed with LVs. 
 
Reference Dose Route Antigen 
Esslinger et al 2 x 107 EFU sc (footpad, tail base) Cw3, mini Melan-A 
Palmowski et al 1 x 106 PFU iv (tail vein) NY-ESO 
Kim et al 1.6 x 106 PFU sc (footpad) TRP-2 
Rowe et al 1 x 107 IU iv (tail vein) OVA 
Dullaers et al 2 x 107 TU sc (footpad) OVA 
He et al 1 x 106 TU sc ( footpad ) OVA 
Chapatte et al 2 x 107 EFU sc (tail base) Melan-A 
Liu et al 2.5 x 107 TU sc (footpad) TRP-1 
Loisel-Meyer 0.15 × 106 TU sc (footpad) CEA 
Rusakiewicz et al 1 x 107 TU sc (footpad) hTERT 
Table 1. Summary of the studies evaluating LVs as an off-the-shelf vaccine. 
Although CD4+ T cell responses were shown to be necessary for the priming and 
maintenance of CTLs when DCs are used for vaccination, not much data is available on the 
role of CD4+ T cell help in the induction of CTLs upon immunization with LVs. Esslinger et 
al (Esslinger et al. 2003) showed that CD4 depletion reduces the primary CTL response upon 
direct administration of LVs. Similarly, we (Dullaers et al. 2006) showed that although there 
was a larger requirement for CD4+ T cell help during the primary response in case of 
immunization with ex vivo transduced DCs compared to direct administration of LVs; CD4+ 
T cell depletion strongly reduced the capacity to mount a recall CTL response in both cases. 
Interestingly, Marzo et al (Marzo et al. 2004) showed that in the case of a VSV infection, a 
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functional CD8+ T cell memory response can be generated in the absence of CD4+ T cells, 
this in contrast to an infection with Listeria monocytogenes. These authors suggest that the 
difference might be due to the fact that VSV can directly infect DC whereas L. monocytogenes 
antigens need to be cross-presented. Since, the currently applied LVs are pseudotyped with 
VSV envelopes, it needs to be further examined to what extent the CTL response is CD4+ T 
cell-dependent.  
The generation of specific T cell responses is a convenient read-out for the success of a 
vaccination strategy however; there are many examples of discrepancies between immune 
responses and anti-tumour responses (Rosenberg et al. 2005). Therefore, it is critical to 
evaluate the effect of LV vaccination on tumour growth. Rowe et al (Rowe et al. 2006) 
showed significantly improved protection of mice vaccinated with LVs encoding OVA 
against a subsequent tumour challenge. Similarly, Dullaers et al (Dullaers et al. 2006) showed 
that direct administration of LVs offers increased protection to a subsequent tumour 
challenge compared to DC vaccination and a significantly improved survival of tumour 
bearing mice. Other studies using TRP-2 (Kim et al. 2005), TRP-1 (Liu et al. 2009) or CEA 
(Loisel-Meyer et al. 2009) as tumour antigen, demonstrated improved survival of tumour 
bearing mice receiving LVs encoding these tumour antigens.  Liu et al (Liu et al. 2009) 
showed that this type of immunization could result in complete regression of small 
subcutaneous tumours, which correlated with enhanced numbers of functional CD8+ T cells 
in the tumour environment. Therefore, these studies highlight the potential of LVs encoding 
tumour antigens as an anti-cancer therapeutic. 
These studies demonstrate that administration of LVs doesn’t provoke immunological 
tolerance, but rather elicits powerful CTL responses against transgene-encoded proteins. 
This suggests a certain degree of immunogenicity of LVs or components within LV 
preparations, leading to activation of innate viral-sensing pathways and as a consequence 
induction of strong adaptive immunity. Therefore, it is not surprising that several studies 
addressed the immunogenicity of LVs. LVs are generally derived from HIV-1, for which 
activation of pDCs through TLR7 triggering has been demonstrated (Fonteneau et al. 2004; 
Beignon et al. 2005). It was demonstrated in vivo that activation of pDCs by recombinant LVs 
is mediated by several mechanisms. Brown et al. (Brown et al. 2006a) reported a TLR7-
dependent type I IFN response, whereas a role for TLR9 was demonstrated by Pichlmair et 
al (Pichlmair et al. 2007), who demonstrated that VSV.G pseudotyped LV preparations 
contain tubulovesicular structures of cellular origin, which carry nucleic acids. These 
structures triggered TLR9 in pDCs, whereas LVs pseudotyped with a γ-retroviral envelope 
didn’t (Lopes et al. 2008), suggesting that this particular mechanism is not necessary for 
potent immune stimulation. More recently, Rossetti et al (Rossetti et al.) demonstrated that 
also human blood-derived pDCs are activated in a TLR7/9-dependent way by LVs in vitro. 
These observations were not surprising as the pDC subset is the DCs subset that is best 
equipped to sense viral infections. However, recombinant LVs also target cDCs. Therefore, 
this DC subset should not be neglected when the LV immunogenicity is discussed. Gruber et 
al (Gruber et al. 2000) reported that transduction of cDCs at low MOI didn’t result in DC 
activation, whereas Tan et al. (Tan et al. 2005) described that transduction of cDCs at high 
MOI results in up-regulation of adhesion, stimulatory and antigen presenting molecules. 
Furthermore, these DCs displayed enhanced allo-stimulatory capacities and an altered 
cytokine secretion pattern. To clarify these results, we (Breckpot et al. 2007b) transduced 
DCs with LVs at varying MOI, confirming that transduction of DCs with LVs at low MOI 
results in considerable transgene delivery, without activation, whereas transduction at high 
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MOI indeed leads to DC maturation. A role for protein kinase R, a cytosolic receptor that 
interacts with double stranded RNA during LV replication, and several TLRs was suggested 
(Breckpot et al. 2007b). In our recent in vivo study, we demonstrated that cDCs are activated 
upon LV infection. More importantly, we showed that this activation was dependent on 
retroviral reverse transcription and critically dependent on the signal adaptor molecules 
MyD88 and TRIF, hence TLR signalling. Experiments with TLR knock out DCs 
demonstrated that both TLR3 and TLR7 are involved in the DC activation (Breckpot et al.).   
It is important to stress that induction of therapeutic anti-tumour immunity is critically 
dependent on an inflammatory environment in order to overcome tolerance, and active 
inhibitory mechanisms exerted by suppressive immune cells, such as Treg, as well as 
tumour cells. Such an inflammatory environment can be achieved by strong activation of the 
innate arm of the immune system, in particular through the engagement of TLRs. This was 
highlighted by Yang et al (Yang et al. 2004) and by Lang et al (Lang et al. 2005), who 
demonstrated that tolerance of antigen-specific CTLs could be broken by persistent TLR 
ligation. In that respect, we demonstrated that DCs activated by LVs via TLR3 and TLR7, 
efficiently expanded antigen-specific CTLs, whereas DCs lacking either TLR lacked this CTL 
inducing capacity (Breckpot et al.). Furthermore, it has been described that signalling 
through certain combinations of TLRs on DCs not only provided a synergy with respect to 
the production of stimulatory cytokines such as IL-12, which is essential in the 
differentiation of CD4+ T cells to a TH1 phenotype (Gautier et al. 2005; Napolitani et al. 2005), 
but also offered protection from suppressive Treg that actively quench the anti-tumour 
immune response (Warger et al. 2006). As a consequence, much research efforts have been 
put in designing approaches that enhance the intrinsic immunogenicity of LV-based 
vaccines. Some of these will be discussed in the next section. 
4.3 Engineering lentiviral vectors to enhance the immune stimulatory capacity of 
dendritic cells  
To enhance the immunogenic potential of LVs, and concomitantly prevent the actions of 
tolerogenic mechanisms over transduced DCs, LVs can be engineered to not only deliver the 
tumour antigen but also deliver molecules that enhance DC activation. Based on our 
growing knowledge on the importance of TLRs for DC activation and which activation 
pathways are triggered by these TLRs, several TLR-based strategies have been developed to 
enhance the immune stimulatory capacity of DCs upon LV transduction.  
Over the years LPS, which binds to TLR4 has been extensively used to activate DCs in vitro 
(Ardeshna et al. 2000; Arrighi et al. 2001; da Silva Correia et al. 2001). LPS-mediated 
activation remarkably enhances stimulation of DC-mediated immune responses in vitro, and 
overcomes suppression by Treg, a critical factor in anti-tumour immunology (Pasare & 
Medzhitov 2003). However, its clinical use is limited by its cytotoxicity. Therefore, the 
feasibility of using RVs encoding a constitutive active TLR4 (caTLR4) for DC maturation has 
been evaluated (Xu et al. 2007). This was achieved by linking the cytoplasmic domain of 
TLR4 to the extracellular single-chain immunoglobulin anti-erbB2. However, no activation 
of an immortalized DC line, JAWSII was observed, although a similar strategy, i.e. 
electroporation with mRNA encoding caTLR4, was recently shown to activate human DCs, 
resulting in priming of Melan-A CTL responses (Bonehill et al. 2008). Using a similar cloning 
strategy Xu et al (Xu et al. 2007) generated RVs encoding MyD88 or IRAK-1, two major 
adaptor molecules in TLR triggered activation pathways. Again they used the JAWSII DC 
line to evaluate the chimeric proteins, demonstrating that only the IRAK-1 chimera 
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mediated IL-12 and TNF-α secretion, and enhanced OVA-specific CD4+ T cell responses. 
Akazawa et al (Akazawa et al. 2007) expressed MyD88 and TRIF, another major TLR signal 
transduction molecule in mouse DCs using LVs. MyD88-modified DCs produced IL-6 and 
IL-12, but didn’t up-regulate phenotypic markers, whereas TRIF expression stimulated IFN-
β production and increased levels of CD86. Both MyD88 and TRIF increased the allo-
stimulatory capacity of the modified DCs, and tumour outgrowth was delayed after 
immunization with these DCs.   
Introduction of MyD88 or IRAK-1 in DCs activates the NF-κB pathway. NF-κB is a well-
studied transcription factor that targets genes associated with DC maturation. Sustained NF-
κB activation in DCs using LVs has been achieved by expressing Kaposi’s sarcoma 
associated human herpes virus vFLIP (Rowe et al. 2009). In this case, DC maturation was 
enhanced by up-regulation of MHC, adhesion (ICAM-1) and co-stimulatory molecules 
(CD80, CD86, CD40), and increased secretion of TNF-α and IL-12. vFLIP-modified DCs 
significantly increased antigen-specific CTL responses resulting in enhanced anti-tumour 
immunity (Karwacz et al. 2009; Rowe et al. 2009). Another effective approach leading to 
sustained NF-κB activation consists of down-regulating the negative feedback molecule, A20 
of which the expression is under the immediate control of NF-κB. A20 deactivates several 
adaptor molecules of the TNFR, IL-1/TLR signalling pathways by ubiquitinating/de-
ubiquitinating activity (Vereecke et al. 2009). Therefore, A20 down-regulation could result in 
prolonged NF-κB activation, resulting in DCs with enhanced stimulatory capacity. LV 
delivered A20-targeted shRNA (Song et al. 2008) and direct introduction of siRNA (Breckpot 
et al. 2009) were applied to down-regulate A20 in mouse and human DCs, respectively. 
These approaches showed that A20 controls DC maturation, cytokine production and 
immunostimulatory potency. Human DCs with down-regulated A20 expression had an 
increased NF-κB activity and showed enhanced and sustained IL-10 and IL-12 secretion. 
These DCs were more potent in stimulating Melan-A CTL responses (Breckpot et al. 2009). 
Mouse DCs with down-regulated A20 expression showed enhanced expression of co-
stimulatory molecules and pro-inflammatory cytokines. Moreover, these DCs hyper-
activated tumour-specific CTL and TH cells, which were refractory to Treg suppression 
(Song et al. 2008).  
Besides LVs that target the NF-κB pathway, LVs have been engineered to increase the DC’s 
immunogenicity by introducing specific genes that modulate intracellular MAPK pathways. 
p38 was activated by expressing MKK6 mutants containing glutamate and aspartate 
residues in their activation loop, mimicking phosphorylated serine or threonine residues 
(Raingeaud et al. 1996). A fusion protein between MKK7 and JNK1 was expressed to achieve 
constitutive JNK1 phosphorylation (Escors et al. 2008). Expression of constitutive activators 
prevents inactivation by phosphatase-dependent negative feedback mechanisms, which 
may counteract tolerogenic mechanisms in anti-tumour immunity. In the absence of TLR 
stimulation, p38 activation resulted in a DC maturation phenotype different from full 
maturation as achieved by LPS treatment (Escors et al. 2008). Particularly, there was specific 
up-regulation of co-stimulatory molecules and absence of significant secretion of pro-
inflammatory cytokines (Escors et al. 2008). Interestingly, co-expression of OVA with the p38 
activator in DCs significantly increased antigen-specific CD4+ and CD8+ T cell responses 
leading to increased anti-tumour immunity (Escors et al. 2008; Karwacz et al. 2009).  
Additionally, MAPK p38 constitutive activation also increased CD8+ T cell responses to 
human tumour antigens NY-ESO in a humanized HLA-A2 mouse model and Melan-A in a 
human DC-T cell culture (Escors et al. 2008). Specific activation of JNK1 in DCs showed only 
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a moderate up-regulation of co-stimulatory molecules and no significant secretion of pro-
inflammatory cytokines, confirming previous studies, which suggested that JNK marginally 
controls DC maturation (Nakahara et al. 2004; Escors et al. 2008).  On the other hand, 
increased antigen-specific CD8+ T cell expansion was achieved in mice after subcutaneous 
vaccination with LV expressing MKK7-JNK1, suggesting that JNK1 may play a subtle but 
important role in DCs in vivo (Escors et al. 2008). 
5. Exploitation of lentivirally transduced dendritic cells for the induction of 
tolerance 
There are many ways in which DCs have been utilised for the treatment of autoimmune 
disorders.  This chapter will focus on genetic modification using LVs, rather than providing 
an extensive review of all DC-based methods.  Because the achievement of immune 
suppression is more challenging than inducing activation, there are a limited number of 
reports on the use of LVs as immunosuppressive (tolerogenic) therapeutic agents.  
An obvious approach to genetically modify DCs for the treatment of autoimmune disorders 
is to express potent immunosuppressive cytokines. In fact, there are a few reports of DC 
modification using mainly RVs expressing immunosuppressive cytokines for the treatment 
of inflammatory diseases (Lee et al. 1998; Takayama et al. 1998; Morita et al. 2001). The 
equivalent approach has been undertaken by transduction of DCs using LVs expressing IL-
10 in an OVA-dependent model of experimental asthma (Henry et al. 2008). In vivo 
intratracheal injection of OVA-pulsed DCs modified with LVs expressing IL-10 effectively 
inhibited airway inflammation and asthma-associated symptoms.  Interestingly, it was 
demonstrated that host IL-10 expression was absolutely required for the IL-10 DCs to inhibit 
asthma (Henry et al. 2008). Therefore, IL-10 expression from DCs was playing an indirect 
role in inhibiting disease. Interestingly, a significant increase in Foxp3+ Treg expressing IL-
10 were expanded, and their adoptive transfer prevented OVA-sensitized mice from 
eosinophilia after OVA challenge (Henry et al. 2008). 
An attractive option for programming tolerogenic DCs is to modulate signalling pathways 
involved in differentiation of immunosuppressive DCs. This approach regulates expression 
of gene clusters, which act in a concerted action in physiological functional tolerogenic DCs. 
There is quite a wide range of experimental evidence linking MAPK ERK activation to 
immune suppression and tolerance (Agrawal et al. 2006; Caparros et al. 2006; Dillon et al. 
2006; Escors et al. 2008). Constitutive activation of the ERK pathway can be readily achieved 
by expression of constitutively active MEK1 mutants, the upstream ERK kinase (Pages et al. 
1994; Raingeaud et al. 1996; Escors et al. 2008; Anastasaki et al. 2009).  Particularly, DCs 
modified with a LV expressing a MEK1 mutant with a deletion in the coding region of the 
nuclear export signal, together with two activating mutations resulted in DCs with a marked 
immature phenotype (Escors et al. 2008). ERK-activated mouse and human DCs showed a 
pronounced CD40 down-regulation and secretion of significant amounts of TGF-β (Escors et 
al. 2008; Arce et al. 2010). These DCs were strongly immunosuppressive, leading to 
differentiation of antigen-specific Foxp3+ Treg in vivo and in vitro (Arce et al. 2010). These 
differentiated Treg strongly proliferated after a second antigen encounter in inflammatory 
conditions. A LV vaccine based on an ERK activator was successfully applied for the 
treatment of inflammatory arthritis in a mouse model (Arce et al. 2010). This therapeutic 
approach could be applied even when the specific arthritogenic antigen was not specifically 
targeted. Application in human therapy could follow a similar approach in which 
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simultaneous ERK activation and expression of an endogenous antigen could be used to 
inhibit arthritis even though the arthritogenic antigens are not well characterized and may 
vary between patients. 
Interestingly, constitutive activation of the type I IFN signalling pathway was also 
immunosuppressive in DCs. Expression of a constitutively active IRF3 mutant (IRF3 2D) in 
mouse DCs induced expression of high levels of IL-10 (Escors et al. 2008). Interestingly, 
vaccination with a LV co-expressing IRF3 2D with an OVA-containing transgene resulted in 
systemic expansion of OVA-specific Foxp3+ Treg (Escors et al. 2008). In physiological 
conditions, phosphorylated IRF3 dimerizes and translocates to the nucleus where it 
transactivates type I IFN promoters, leading to IFN-β production, a potent antiviral cytokine 
(Fitzgerald et al. 2003). Interestingly, it has been known for some time that components of 
the type I interferon pathway are in fact immunosuppressive (Chang et al. 2007). This is also 
the basis of the use of type I IFNs for the treatment of multiple sclerosis (Comabella et al. 
2002; Billiau 2006). Very interestingly, production of both IFN-β and IL-10 share a common 
pathway when activated by TLR signalling (Hacker et al. 2006; Chang et al. 2007). It has been 
proposed that phosphorylated IRF3 may link IFN-β production with IL-10 secretion through 
a MyD88-dependent pathway (Escors et al. 2008). Taking advantage of this, activators of the 
type I IFN pathway could be expressed in DCs for the treatment of autoimmune disorders 
such as multiple sclerosis.  
An alternative to constitutive activation of immunosuppressive pathways is to specifically 
inhibit pro-inflammatory signalling pathways.  Possibly, one of the major pro-inflammatory 
pathways in DCs is NF-κB (Breckpot & Escors 2009b). Consequently, silencing of 
components from the NF-κB pathway could theoretically prevent DC maturation and 
induce immune suppression and tolerance. For instance, this has been successfully applied 
by silencing Rel-B in DCs by delivery of a specific shRNA using LVs (Zhang et al. 2009). Rel-
B silencing was sufficient to confer DCs resistance to TLR-derived maturation signals and to 
inhibit experimental autoimmune myasthenia gravis in a mouse model (Zhang et al. 2009). 
Interestingly, just by inhibiting NF-κB, DCs acquired tolerogenic activities characterised by 
inhibition of T cell proliferation and differentiation of Foxp3+ Treg.  
Another interesting approach is the exploitation of naturally occurring negative feedback 
mechanisms of pro-inflammatory pathways. This has been achieved by over-expressing 
suppressor of cytokine signalling 3 (SOCS-3) in DCs using LVs (Li et al. 2006). SOCS comprise 
a family of cytoplasmic proteins induced by cytokine-mediated signal transduction. They form 
part of a negative feedback mechanism that limits cytokine-induced signalling. Expression of 
SOCS3 in mouse DCs results in immature DCs with down-regulated MHC molecules and 
reduced CD86 (Li et al. 2006). These modified DCs exhibit an impaired signalling by IL-12 and 
IL-23, and reduced expression of these cytokines. More importantly, enhanced secretion of IL-
10 was observed, which polarised T cell responses towards a TH2 type.  Interestingly, SOCS3-
expressing DCs could efficiently inhibit the development of EAE, an experimental model for 
human multiple sclerosis (Li et al. 2006). 
Recently, a LV-based shRNA delivery system was successfully applied for the treatment of 
experimental collagen-induced arthritis without specific targeting of the arthritogenic 
antigen (collagen) (Lai Kwan Lam et al. 2008). Direct administration of a LV encoding a 
siRNA specific for B cell activating factor (BAFF) to the inflamed joint was sufficient to 
inhibit arthritis. BAFF is a member of the TNF family which is mainly involved in regulating 
B cell maturation and functions (Batten et al. 2000; Yang et al. 2010). Interestingly, elevated 
BAFF levels have been found in the serum of patients suffering from several autoimmune 
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disorders including rheumatoid arthritis. Very interestingly, it was demonstrated that LVs 
preferentially transduced DCs in the inflamed joint, and that BAFF silencing in these DCs 
interfered with DC maturation. Local BAFF silencing inhibited pro-inflammatory T cell 
development and inhibited production of pro-inflammatory cytokines such as IL-17, IL-23 
and IL-6 (Lai Kwan Lam et al. 2008). Importantly, these authors clearly demonstrated that (i) 
LVs can be directly administered to the site of inflammation, (ii) they preferentially 
transduce local DCs and (iii) it is not strictly necessary to target the arthritogenic antigen. 
In addition to manipulation of signalling pathways, there are small peptides with broad 
activities including immune suppression. Direct intraperitoneal immunisation with a LV 
encoding vasointestinal peptide (VIP) reduced the severity of collagen-induced arthritis in a 
mouse model (Delgado et al. 2008). Interestingly, vaccination with this LV significantly 
inhibited the secretion of a wide array of pro-inflammatory cytokines both systemically and 
in the joint. This tolerogenic LV-vaccination expanded Foxp3+ Treg (Delgado et al. 2008). 
However, VIP has a variety of physiological functions apart from its immunosuppressive 
properties. Therefore, in this case, it would be desirable to modify DCs ex vivo with a VIP-
expressing LV followed by in vivo transfer (Toscano et al. 2010). In fact, VIP expression in 
DCs was sufficient to keep them in an immature stage, leading to secretion of high levels of 
IL-10 (Toscano et al. 2010). In vivo administration of VIP-expressing DCs had beneficial 
therapeutic effects in EAE mice and in the cecal ligation and puncture model, both models 
relevant for multiple sclerosis and sepsis in humans (Toscano et al. 2010). 
6. Limitations of lentiviral vectors for direct in vivo application  
Although the HIV-based vector system is by far the best developed among the various LVs, 
a variety of quality, safety, efficacy, regulatory and ethical concerns slacken the frequent 
employment of HIV-based vectors in a clinical setting. In view of DC modulation, the scope 
of this review will be limited to the biological risks and immunogenic consequences of LV-
based vaccination. Safety seems the most pressing issue as LVs are derived from an 
integrating pathogenic agent, lethal in humans. As mentioned, one of the main adverse 
events to consider is the potential generation of RCLs. However, to date no RCLs have been 
reported for LV packaging systems. This can be partially explained by the separation of cis-
and trans-acting sequences during LV production, but also by the fact that SIN LVs are less 
likely to produce RCLs (Pauwels et al. 2009). A major setback for viral gene therapy clinical 
trials was caused by the development of leukaemia in five patients of two separate γ-RV 
gene therapy trials for X-linked SCID as a consequence of insertional activation of the LMO2 
gene (proto-oncogene) by the LTR enhancer. As genomic integration is common to all 
retroviruses, the associated risk of insertional mutagenesis and/or transactivation of 
adjacent sequences must be taken into account for LVs as well (Howe et al. 2008). However, 
as these observations were made with γ–RV it would be to hasty to extrapolate this risk to 
the multiply attenuated recombinant LV system used today. An in vitro mapping study 
comparing RV and LV integration in transduced human HSCs revealed that RV but not LV 
hot spots were highly enriched in proto-oncogenes, cancer-associated and growth-
controlling genes, suggesting that LVs have a lower propensity for integrating in potentially 
dangerous regions within the human genome (Cattoglio et al. 2007). Furthermore, an in vivo 
genotoxicity assay using a tumour-prone murine model, also showed differences in the 
oncogenic potential of RVs and LVs. Herein, it was shown that LTRs co-determine the 
vector’s genotoxic potential, supporting the choice of SIN LVs (Montini et al. 2009). Recently, 
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immune-deficient mice received LV transduced HSCs, and were followed for 2-6 months. 
No LV-associated adverse events were observed, and none of the mice had detectable levels 
of HIV p24 antigen in their sera (Bauer et al. 2008). More recently also the concept of clonal 
dominance came forward for LVs in a phase I/II clinical trial using HSCs transduced by a 
SIN LV with chromatin insulators (Bank et al. 2005). This clonal dominance seems to be due 
to growth and/or survival advantage conferred by gene-activating or -suppressing effects of 
the integrated LV. Importantly, such induced clonal dominance didn’t lead to malignant 
transformation (Fehse & Roeder 2008). Additional potential adverse events are 
seroconversion of the subject to components of the HIV-1 vector, mobilization and 
subsequent spread of mobilized vector particles to previously untransduced cells and 
tissues, and transmission of exogenous DNA to cells of the germ line (Romano et al. 2003). 
In view of LV based vaccination, the induced innate and adaptive immune reactions 
against the LV particle, transduced cells and/or its transgene product, act as a double-
edged sword. This immunogenicity may aggravate a robust immune reaction, which is 
possibly advantageous in the context of e.g. anti-tumour immunotherapy. However, 
unwanted immune responses may curtail the induction of tolerance, which is desired for 
the treatment of e.g. transplantation rejection or autoimmune diseases. As broad tropism 
LVs are capable of transducing DCs but also other cell types, this can have important 
consequences in view of the immunological outcome. On the one hand transgene 
expression by non-DCs could lead to uptake of cellular remains from these cells by DCs 
followed by antigen presentation in the context of MHC class II and via cross-presentation 
in the context of MHC class I. In this way not only a CTL response is triggered, but also 
TH cells, which are important to induce a proper CTL response (Matrai et al. 2010). On the 
other hand DCs also play an important role in the induction and maintenance of 
peripheral tolerance against self-antigens (Steinman 2007). In this context, persistent 
expression of the transgene by a non-DC, as a consequence of LV integration in a 
terminally differentiated long-living cell, could also lead to induction of peripheral 
tolerance (Follenzi et al. 2004). Thus, upon broad tropism LV vaccination, the antigen-
specific immune response could be initiated by transduced DCs (direct priming), and 
theoretically by non-lymphoid cells (cross-priming). However, the latter might also 
counteract the envisaged immune response, which makes it hard to predict the 
immunological outcome. Therefore, targeting of LVs to DCs, the cell type of choice to 
induce immunity or tolerance has been explored. Two different approaches have been 
successfully attempted (i) transcriptional targeting in which DC-specific promoters are 
exploited and (ii) transductional targeting in which DC-specific LV entry is achieved. 
Transcriptional targeting has been extensively discussed by Frecha et al (Frecha et al. 
2008). 
We believe that transductional targeting of LVs to DCs is a very interesting strategy to tackle 
safety and efficacy concerns all at once, since: (i) DCs have a relative short half-life, which 
decreases the chance for malignant transformation after insertional mutagenesis, since this is 
a multi-step process (Fehse & Roeder 2008), (ii) there is no risk for transmission of 
exogenous DNA to the germ line, (iii) non-DC transduction is prevented which can 
overcome unwanted interference with the desired immune response, (iv) DC subset-specific 
targeting paves the way to fundamental research on the exact role of each DC subset in the 
development of diseases, as well as their therapeutic importance.  
As the LV tropism is determined by the envelope glycoprotein, pseudotyping allows the 
generation of LVs with a specific transduction pattern. To date, there is no natural DC-
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specific envelope glycoprotein identified. In first instance, it was attempted to modify 
existing envelope proteins by means of genetic engineering to obtain DC-specific binding 
without disrupting membrane fusion. An example of this application is the construction of a 
LV where the VSV.G envelope is replaced by a chimeric version of a scFv, coupled to a (i) N-
terminal end of the VSV.G protein (Dreja & Piechaczyk 2006), (ii) the amphotrophic MLV 
protein (Gennari et al. 2009), (iii) the sindbis virus envelope protein  (Morizono et al. 2009; 
Zhang et al. 2010) or (iv) the H-protein of the measle virus envelope, which is than combined 
with its F-protein (Ageichik et al.). However, these manipulations result in viral particles 
with low stability and limited binding- and fusion capacities. Alternatively, the sindbis 
glycoprotein can be mutated in its heparin sulphate receptor (HSR) binding part whereby it 
exclusively binds to DC-SIGN, a DC-specific glycoprotein (Yang et al. 2008). Importantly, 
with this strategy DC-specific transduction could be demonstrated in vivo. It was moreover 
demonstrated that a strong T cell response could be generated that induced tumour 
regression. An alternative method to target LVs to specific cell types was proposed by 
Chandrashekran et al (Chandrashekran et al. 2004). Since RVs and LVs obtain their envelope 
after budding from the cell membrane of the producer cell line, every glycoprotein that is 
expressed on this membrane, will be incorporated in the viral envelope. Through this 
mechanism a membrane bound form of stem cell factor (mbSCF) was incorporated in the 
membrane of a RV producing cell line, which produced ecotropic RVs. This envelope 
doesn’t allow transduction of human cells. However, binding of the mbSCF onto its 
receptor, c-kit, resulted in the transduction of human c-kit+ cells by the mbSCF-containing 
and ecotropic envelope pseudotyped RVs. This strategy was later on expanded by Yang et al 
to LVs (Yang et al. 2006). They incorporated a fusogenic protein (derived from influenza A 
or sindbis virus), as well as an antibody against CD20 in the plasmamembrane of the LV 
producing cell line. Subsequently LVs were produced, which transduced B cells both in vitro 
and in vivo. Importantly, Zhang et al (Zhang et al.) engineered a truncated version of VSV.G 
(VSV.GS), which resulted in a binding-defective, but fusogenic envelope, which still confers 
vector stability hence allows production of high titer LVs. It was shown that LVs that 
incorporate the VSV.GS together with mbSCF in their viral surface efficiently transduced c-
kit+ cells. This strategy could be translated to DCs, where DC-specific molecules, such as 
BDCA-2 or DEC-205 are targeted (Dzionek et al. 2001; Bonifaz et al. 2004; Yang et al. 2008).  
As molecular cloning of classic antibodies or fragments thereof is challenging, alternatives 
have been explored. One of these is the use of antibodies from members of the family of 
Camilidae (i.e. dromedaries, camels, llamas), which produce a unique class of antibodies 
composed of two identical heavy chains as opposed to the conventional (four-chain) 
antibody repertoire (Hamers-Casterman et al. 1993). The antigen-binding part of the 
molecule is composed of only one single variable region (termed VHH, or Nanobody, Nb). 
These antigen-specific antibody fragments offer many advantages: (i) they are highly 
soluble, (ii) they can refold after denaturation whilst retaining their binding capacity, (iii) 
cloning and selection of antigen-specific Nbs obviate the need for construction and 
screening of large libraries, (iv) as Nbs can be fused to other proteins, it should be possible 
to present them on the cell membrane of a producer cell line, thus generating LVs that 
incorporated a DC-specific Nb in their envelope during budding as described above . 
7. Conclusion and future perspectives 
To date, numerous studies have demonstrated that LVs are excellent candidates for the 
treatment of immunological pathologies such as cancer and infectious diseases. This can be 
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explained by their capacity to transduce DCs in vivo, which is followed by efficient 
expression, processing and presentation of the introduced transgenes via MHC class I and 
class II molecules, thereby (re) activating an effector and TH1 response, respectively. 
Although LVs comprise an intrinsic immunogenic potential, crucial for effective activation 
of transduced DCs, they have been exploited as a means to induce antigen-specific tolerance 
for the treatment of diseases with an autoimmune aetiology and transplantation rejection as 
well. Although this seems contradictory, this duality endows the LV with the potential to 
become the vaccine tool of choice with an infinite number of application possibilities. 
Although we are convinced of the LVs’ potential as an immunotherapeutic, we give a 
concise overview of the extra improvements we believe are necessary to moderate the 
translation of the LVs from bench to bedside.  
 
 
Fig. 4. Schematic representation of what we believe is the ultimate strategy to successfully 
exploit the advantageous of LVs and DCs for immunotherapeutic purposes. Herein, LVs 
encoding antigen and immune modulating molecules are pseudotyped with a binding-
defective but fusogenic envelope glycoprotein, as well as a DC-specific Nb (1).  The latter 
will dictate binding of the LVs to DCs, after which the envelope mediates fusion (2). 
Subsequently, the DCs are rendered immunogenic or tolerogenic, depending on the 
envisaged therapy, and the DCs present antigen-derived peptides in the context of MHC 
class I and class II molecules, hence induce effector T cells or Treg (3).  
A first improvement will be the overall use of third generation LVs to curtail the risk of 
RCLs. Secondly, the use of NILVs is believed to be an inevitable strategy to diminish the 
LVs’ potential to induce insertional mutagenesis. A third improvement to increase both 
safety and efficacy lies within transductional targeting of the LV to DCs in vivo. Therefore 
we propose to exploit the Nb display technology to target LVs to DCs in combination with 
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LV-based modulation of two signal transduction pathways within the DCs (Fig. 4). The Nb 
display technology is based on the natural budding mechanism of LVs as they are released 
from the LV producing cell. This mechanism allows the incorporation of a binding-defective 
but fusogenic glycoprotein together with a DC-specific Nb in the plasmamembrane of the 
LV producer cells and subsequently in the viral envelope. The DC-specific Nb will bind to 
its antigen on the DC surface whereupon the fusogenic envelope induces transduction. In 
this way LVs shuttle their cargo into the DC. Subsequently DCs can be conditioned to 
become either stimulatory or tolerogenic for the introduced transgene(s). For this purpose 
we can modulate adaptor molecules, such as the MAPK ERK, which switches on a 
tolerogenic pathway (Arce et al.) or A20, which inhibits the stimulatory NF-κB pathway 
(Song et al. 2008). Down-regulation of both will elevate the DC’ immunogenic potential, 
whereas their up-regulation could ameliorate its tolerogenic potential. We strongly believe 
that this strategy can pave the way toward a safe and multifunctional LV toolbox. 
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